The aberrant expression of Pknox1 is associated with hepatic glucose and lipid dysmetabolism status of type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). However, the underlying mechanism causing Pknox1 overexpression in this pathological status remains unclear. By using miRNA target prediction programs, we found that the 3′-UTR of the Pknox1 mRNA sequence contains highly conserved target sites of miR-17 family. In a rat model of streptozotocin and highfat diet-induced T2DM and NAFLD complication, the increased hepatic expression of Pknox1 was consistent with decreased expressions of miR-17 family, especially miR-17 and miR-20a. Furthermore, an inverse correlation was observed between Pknox1 and miR-17 and miR-20a in free fatty acids-induced hepatocyte steatosis.
Transcription factor Pknox1 belongs to the three-amino acid loop extension class of homeodomain proteins and is ubiquitously expressed both in fetal and adult mice and can form tripartite DNAbinding complexes with members of the Hox and Pbx protein families. 3 Pknox1 is essential at multiple stages of embryonic development. 4 In mouse, Pknox1-null embryos die before gastrulation, because epiblast cells undergo p53-dependent apoptosis. 5 Whereas, mouse embryos carrying a hypomorphic Pknox1 i/i mutation (expressing about 5% protein compared with WT) show a leaky embryoniclethal phenotype and defects in angiogenesis, hematopoiesis, and eye development. 4, 6, 7 Thus, Pknox1 is previous known as a tumor suppressor associated with the maintenance of genomic stability.
Recently, several studies have shown that Pknox1 was also involved in hepatic lipogenesis and insulin-dependent glucose homeostasis. complicated with NAFLD. 9 However, the underlying mechanism causing Pknox1 overexpression in this pathological status remains unclear.
MicroRNAs (miRNAs) are small noncoding RNAs that can cause mRNA degradation or translation inhibition by interacting with the 3′-untranslated region (3′-UTR) of the target gene mRNA. 10, 11 Accumulated evidences have shown that miRNAs play crucial roles in the development of metabolic disease through regulating the expression of glucose and lipid metabolism and IR-related genes. 12 For example, miR-122, as the predominant liver miRNA, has been proposed to play a central role in the maintenance of lipid and glucose homeostasis, it regulates hepatic fatty acid oxidation and cholesterol metabolism by way of downregulation of genes involved in choles- (1 mU/g body weight) at 10 minutes prior to being killed.
| Histological analysis
Formalin-fixed, paraffin-embedded specimens were cut into 8 μ mol L −1 serial sections and subjected to standard hematoxylin and eosin (H&E) staining for histological examination. HepG2 and L02 cells grown in 6-well plates were washed with PBS and fixed with 10% neutral formalin, followed by staining with Oil Red O and hematoxylin. Sections and cells were imaged at 400× magnification (Olympus, Japan).
| Biochemical analysis
Serum biochemical parameters including triglyceride (TG), alanine aminotransferase aspartate (ALT), aspartate transaminase (AST) levels were detected, using a Hitachi 7600 autoanalyzer (Hitachi, Tokyo, Japan), employing standard procedure. Blood glucose (GLU) was detected by Accu-Chek Performa (Roche, Switzerland). method was applied to quantify the expression levels of miRNAs.
| Cell culture and treatments
Data are normalized over the average CT value of U6, and 2
−ΔΔCT method was used to determine relative miRNA expression.
| Western blotting
Liver samples or hepatocyes were lysed with RIPA peptide lysis buf- (1:1000; Cell Signaling Technology), and anti-β-actin (1:3000, Huabio, China). Protein bands were developed using the Enhanced Chemiluminescence (ECL) system and were visualized by using the ChemiScope Western Blot Imaging System (Clinx Science Instruments Co., Ltd). The gray-scale value assay was performed by using Image J software (Rawak Software, Inc. Germany).
| siRNA, miRNA and plasmid transfection
SiRNA against Pknox1 (si-Pknox1) and scrambled siRNA (si-Ctrl)
were purchased from RiboBio. The mirVana miRNA mimics and inhibitors for miR-17 and miR-20a and the negative control (miR-NC)
were purchased from Ambion (Thermo fisher scientific). Pknox1 overexpression plasmid was constructed by Vigene biosciences.
SiRNA and plasmid transfection was carried out using lipofectamine ™ 3000 (Thermo fisher scientific), miRNA transfection was carried out using lipofectamine ™ RNAiMAX (Thermo fisher scientific)
according to the manufacturer's instructions. At 24 hours after transfection, the effects of siRNA-or miRNA-mediated gene silencing and translational regulation were measured by western blot analysis.
| Dual-luciferase assay
The 3′-UTR of Pknox1 containing the predicted miR-17-binding sites was amplified and subcloned into the pmiR-RB-REPORT ™ vector to generate the Pknox1 Dual-Luciferase expression vector (Pknox1-WT). Mutations were performed, using a fast mutation kit (NEB, Canada) to generate Pknox1-Mut1, Pknox1-Mut2, and Pknox1- 
| Statistical analysis
Differences between groups were analyzed, using conventional Student's t test or ANOVA. Each experiment was repeated at least three times, and the data are presented as mean ± SD. A P < 0.05 was considered to be statistically significant.
| RESULTS

| Hepatic Pknox1 expression level is inversely correlated with miR-17 family
To address the significance of hepatic Pknox1 to the T2DM complicated with NAFLD, we first examined its expression in the rat model of STZ and HFD-induced T2DM/NAFLD. Increased intrahepatic fat accumulation was confirmed by H&E staining of liver sections (Figure 1A) . Consistent with the pathologic alteration, the serum GLU, TG, ALT, and AST levels and hepatic Pknox1 expression level were increased with the modeling time ( Figure 1B,D) . Moreover, the serine phosphorylation of the insulin receptor substrate 1 (IRS1) was significantly increased, indicating that insulin receptor signaling was also impaired in this model ( Figure 1D ). However, there were no significant differences in the levels of these metabolic parameters and hepatic PKNOX1 among the age-matched control rats (8-, 10-, 14-week-old) with normal feeding ( Figure S1 ). These data suggest that the increased hepatic Pknox1 may be specifically associated with the aberrant metabolism status in T2DM/NAFLD model.
Subsequently, by using three publicly available algorithms (TargetScan, miRanda, and PicTar), we found that the 3′-UTR of the Pknox1 mRNA sequence contains two highly conserved target sites of miR-17 family ( Figure S2 ). We then examined the expression levels of miR-17 family in the liver samples of the T2DM/NAFLD YE ET AL. Besides miR-17 family, miR-223 was shown to target and inhibit Pknox1 gene expression. 23 We also found that the hepatic level of miR-223 was gradually decreased by HFD-feeding and STZ administration. However, there is no obvious change of miR-223 level in the hepatocytes cultured by FFA containing medium as compared to those by normal medium ( Figure S4 ). It may be due to the specific expression tendency of miR-223, which is preferentially expressed in the hematopoietic system and is considered to play important roles in the differentiation of hematopoietic stem cells, myeloid, erythroid and lymphoid cells. 24 Thus, the dysregulation of miR-223 maybe presented mainly in hepatic macrophage and affects its function by targeting Pknox1. The study by Zhuang et al. support and complement our speculation. They revealed that miR-223 was a crucial regulator of macrophage polarization by way of inhibiting Pknox1 and then protected against diet-induced adipose tissue inflammatory response and systemic IR. 23 In contrast to macrophages, the expression of Pknox1 in hepatocytes was shown to be regulated mainly by miR-17
family. In FFA-induced hepatocyte steatosis, the hepatic expression level of Pknox1 was inversely correlated with miR-17 and miR-20a.
In addition, mutation of either miR-17 family-targeted MREs or of both two MREs in the Pknox1 mRNA 3′-UTR resulted in an increase in luciferase expression as compared to the wild-type reporter construct, which further verified an indeed regulatory relationship between the miR-17 family and the Pknox1 mRNA.
Moreover, supplement the level of miR-17 or miR-20a in hepatocytes by transfection with their mimics was shown to suppress Pknox1 expression and then enhanced insulin receptor signaling and reduced intracellular TG and lipid accumulation in hepatocytes.
These observations indicate that it is possible that miR-17 family mimics would serve as a novel approach for prevention and treatment of T2DM and NAFLD complication. However, to further determine the therapeutic effectiveness of miR-17 family-mediated regulation of Pknox1 in glucose and lipid metabolism disorders, the results from in vitro studies were verified in in vivo studies.
In conclusion, this study reveals that the downregulation of miR- 
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